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a b s t r a c t
Cannabis users are more likely to have psychotic experiences (PEs). The degree to which these
associations are driven by genetic or environmental inﬂuences in adolescence is unknown. This study
estimated the genetic and environmental contributions to the relationship between cannabis use and
PEs. Speciﬁc PEs were measured in a community-based twin sample (4830 16-year-old pairs) using self-
reports and parent-reports. Adolescents reported on ever using cannabis. Multivariate liability threshold
structural equation model-ﬁtting was conducted. Cannabis use was signiﬁcantly correlated with PEs.
Modest heritability (37%), common environmental inﬂuences (55%) and unique environment (8%) were
found for cannabis use. For PEs, modest heritability (27–54%), unique environmental inﬂuences (E¼12–
50%) and little common environmental inﬂuences (11–20%), with the exception of parent-rated Negative
Symptoms (42%), were reported. Environmental inﬂuences explained all of the covariation between
cannabis use and paranoia, cognitive disorganization and parent-rated negative symptoms (bivariate
common environment¼69–100%, bivariate unique environment¼28–31%), whilst the relationship
between cannabis use and hallucinations indicated familial inﬂuences. Cannabis use explains 2–5% of
variance in positive, cognitive, and negative PEs. Cannabis use and psychotic experience co-occur due to
environmental factors. Focus on speciﬁc environments may reveal why adolescent cannabis use and
psychotic experiences tend to ‘travel together’.
& 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Psychotic experiences (PEs) are common within the general
population (Poulton et al., 2000; Olfson et al., 2002; Polanczyk
et al., 2010) and are associated with many negative consequences,
including increased risk of suicide (Kelleher et al., 2012). They
been found to precede the onset of psychosis amongst some
individuals (Kelleher and Cannon, 2011), thus making them an
early risk factor for clinical disorder. Examining correlates asso-
ciated with psychosis may assist in gaining a greater insight into
the etiology of PEs. An example of such a correlate is cannabis use.
The relationship between cannabis use and psychotic disorders
has been demonstrated amongst adult sub-clinical and clinical
populations, with estimates of an approximate 2-fold increased
risk of developing psychotic disorder in individuals who regularly
use cannabis from an early age, over and above pre-existing
vulnerabilities to psychosis (i.e. earlier psychotic symptoms and
environmental risk factors such as trauma) (Henquet et al., 2005a,
2005b). Studies amongst adolescent sub-clinical populations have
also linked cannabis use with increasing risks for PEs (Fergusson
et al., 2003; Henquet et al., 2005a, 2005b; Hides et al., 2009; Van
Gastel et al., 2012) (r¼0.12–0.23) (Grifﬁth-Lendering et al., 2013).
Increased levels of both positive and negative dimensions of PEs
have been observed amongst individuals who reported using
cannabis in early adolescence (i.e. under 15-years) (Stefanis
et al., 2004). This association has been extended to show a dose
response effect whereby the risk of PEs was found to increase with
the frequency of cannabis use over time (Henquet et al., 2005a,
2005b). Longitudinal investigations into the direction of effect
between cannabis use and PEs suggest that cannabis use increases
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individuals’ vulnerability for psychotic symptoms (Henquet et al.,
2005a, 2005b). This ‘vulnerability’ directional hypothesis has been
reinforced by research in neurophysiology, which has shown that
cannabis use can affect brain chemistry. It is proposed that
cannabinoids, such as tetrahydrocannabinol (THC) found in can-
nabis, release the neurotransmitter dopamine (Iversen, 2003),
which in turn has been implicated in the neuropharmacology of
psychosis (Bowers and Kantrowitz, 2007), thus outlining (albeit
brieﬂy here) a biological pathway from cannabis use to psychosis.
Furthermore, exposure to THC has also been associated with
engaging the endocannabinoid system, which modulates the
inhibitory and excitatory synapses in the brain, regulates emotion
and motivation and is involved in the formation of habit and
implicit learning (Van Winkel and Kuepper, 2014). As disruption of
the endocannabinoid system has been associated with symptoms
of psychosis (Leweke and Koethe, 2008), it is possible that the
endocannabinoid system may be an underlying biological mecha-
nisms contributing to the association between cannabis use and
PEs. Furthermore as adolescence has been noted as a sensitive
period of time for the development of the endocannabinoid
system (Rubino et al., 2012), atypical activity in this system of
the brain may hold particular salience for the emergence of
psychotic experiences in adolescences. In addition, neuroimaging
data suggests that the induction of PEs by THC is mediated by its
effects on the prefrontal and the medial cortex (Bhattacharyya
et al., 2009, 2012). Using data collected from adolescents within
the general population, we tested the hypothesis that ever using
cannabis will be associated with PEs.
Although cannabis use is associated with elevated levels of PEs, the
majority of cannabis users do not report PEs (Henquet et al., 2008).
Differential factors may be present, which increase the risk of PEs
amongst some cannabis users but not others. Family studies have
shown that the risk for psychosis and psychosis-related outcomes
amongst cannabis users is similar within siblings (McGrath et al.,
2010) and higher amongst those with ﬁrst degree relatives with
psychosis (Genetic Risk and Outcome in Psychosis (GROUP), 2011),
thus suggesting that there may be some familiality shared between
cannabis use and psychosis. Familiality can reﬂect shared genetic
vulnerability or shared environment (environmental inﬂuences that
make children growing up in the same family similar (Plomin et al.,
2013)). Investigations into the potential role of genetic factors have
shown differences in behavioural and physiological effects of experi-
mentally administered THC to be moderated by variation in genes
implicated in neurotransmitter metabolism (Bhattacharyya et al.,
2012). Furthermore, gene-environment interaction studies have pro-
vided mixed support for a moderating effect of genes (e.g. catechol-O-
methyltransferase (COMT) and AKT1 gene) on the association between
cannabis use and psychosis (Casadio et al., 2011). It is unknown the
extent to which net genetic factors have a role in the relationship
between cannabis use and PEs. Furthermore, cannabis use is in part
heritable which is not taken into account in GE analyses, which
assume it operates as a purely environmental variable.
Evidence from epidemiological studies suggests that the risk of
psychotic symptoms is higher amongst individuals who use
cannabis and have a family history of schizophrenia. There is also
evidence to support that a genetic vulnerability to psychosis
increases the risk amongst cannabis users to develop psychotic
symptoms (Arseneault et al., 2002; Verdoux et al., 2003), thus
suggesting that a shared genetic propensity may underlie the
association between cannabis use and psychotic experiences.
Furthermore, additive genetic inﬂuences explain a proportion of
variance in both cannabis use (40–59%) (Verweij et al., 2011) and
PEs (33–58%) (Polanczyk et al., 2010; Ericson et al., 2011; Hur et al.,
2012; Zavos et al., 2014); hence they may covary because the same
common genetic inﬂuences underlie both of these phenotypes.
Cannabis use and PEs are also inﬂuenced by environmental factors,
thus questioning whether similar environmental correlates of
cannabis use and PEs contribute to their covariation. For example
peer victimization has been associated with emerging psychotic
symptoms (Arseneault et al., 2011) and substance use (Tharp-Taylor
et al., 2009) amongst adolescents. Similarly there is also some
evidence to support the association between socioeconomic dis-
advantage with emerging psychotic symptoms (Morgan et al.,
2009) and substance use (Daniel et al., 2009), thus alluding to the
potential for environmental factors to act as explanatory mechan-
isms underlying the association between cannabis use and PEs.
Cannabis use has also been found to increase the risk of trauma (i.e.
maltreatment) based vulnerabilities for psychosis (Shevlin et al.,
2009), thus identifying trauma as a potential ‘environmental’ risk
factor which contributes towards the association between cannabis
use and psychotic experiences. However it is important to note that
psychotic experiences are not the same as clinical psychosis and
therefore inferences from studies investigating psychosis should be
undertaken with caution.
The role of genetic and environmental inﬂuences on the
covariation between cannabis use and PEs has not been tested
formally and is done for the ﬁrst time here. Our aims for this study
were twofold, ﬁrst to examine if cannabis use is associated with
speciﬁc PEs (including the range of positive, cognitive and negative
experiences) in adolescence. Second, to estimate the extent to
which genetic and environmental factors inﬂuence the association
between cannabis use and PEs.
2. Methods
2.1. Sample
The Longitudinal Experiences And Perceptions (LEAP) study (Ronald et al.,
2014) involves participants from the Twins Early Development Study (TEDS), a
community sample of monozygotic (MZ) and dizygotic (DZ) twins born in England
and Wales between 1994 and 1996. Zygosity of participants was assigned using a
parent-reported questionnaire of physical similarity, which is over 95% accurate
when compared to DNA testing (Price et al., 2000). For cases where zygosity was
unclear, DNA testing was conducted.
On average 93% of participating families were White Caucasian, 38% had parents
with A-levels (UK advanced educational qualiﬁcation) or higher educational qualiﬁca-
tions, 45% had mothers who were employed and 92% had fathers who were employed
(Haworth et al., 2013). This is representative and equivalent to UK population
percentages for this generation, being 93% White Caucasian; 32% for A-levels or
higher; 49% for mother employed; and 89% for father employed (Walker et al., 2001).
TEDS has full ethical approval and written consent was obtained at point of contact.
10,874 families from TEDS were invited to take part in the LEAP study. Parent
reports for 5076 (47%) families and twin reports for 5059 (47%) pairs were obtained.
Adolescents involved in the LEAP project had a mean age of 16.32 years. Individuals
were excluded (N¼327 families) if they did not provide consent at ﬁrst contact (when
TEDS was started), if they had a severe medical disorder, had experienced severe
perinatal complications or if their zygosity was unknown. After exclusions, the sample
reported on in this study comprised of 4830 families (45% male, 36% MZ twin pairs). In
the sample 94% wasWhite Caucasian and 16% had mothers with one or more A-levels
(UK advanced educational qualiﬁcation) as highest qualiﬁcation. Amongst those who
did not participate 91% of the sample wasWhite Caucasian and 12% had mothers with
one or more A-levels as highest qualiﬁcation. Data was collected using postal
questionnaires, where participants and their parents were asked to answer questions
on participants’ perceptions and experiences.
2.2. Measures
2.2.1. Cannabis use
We assessed cannabis use by asking participants “Have you ever tried cannabis”,
to which they responded “Yes”(1) or “No”(0). Participants were informed of other
names often used to describe cannabis such as “hash”, “weed”, “dope”, and “pot”, to
ensure that all instances of cannabis use were captured.
2.2.2. Psychotic experiences
Psychotic experiences (PEs) were assessed at age-16 using the Speciﬁc Psychotic
Experiences Questionnaire (SPEQ) (Ronald et al., 2014). SPEQ assesses speciﬁc PEs as
quantitative traits and includes ﬁve self-report subscales: paranoia (15 items),
hallucinations (9 items), cognitive disorganisation (11 items), grandiosity (8 items),
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anhedonia (10 items) and one parent-rated subscale: parent-rated negative symp-
toms (10 items). SPEQ items were derived for the most part from existing scales that
were adapted to be suitable for adolescents. Response scales related to frequency of
experiences for paranoia and hallucinations (“Not at all” (0),“Rarely” (1), “Once a
month” (2),“Once a week” (3), “Several times a week” (4), “Daily” (5)), as per
previous instruments, the other SPEQ scales asked about presence of experiences or
how true the statements about experiences were for the individual (e.g. for parent-
rated negative symptoms, “Not at all true” (0), “Somewhat true” (1), “Mainly true”
(2), “Deﬁnitely true” (3)) (Ronald et al., 2014). Grandiosity and anhedonia subscales
asked about psychotic experiences within the last month, the parent-rated negative
symptoms measure asked about experiences within the last six months. The
remaining three scales did not specify a reporting period. In addition to self-report
of anhedonia, parent rated reports on negative symptoms were collected in line with
recent recommendations that observer ratings should be used instead of or in
addition to self-ratings (Blanchard et al., 2011).
The subscales were derived from principal component analysis and show good-
to-excellent internal consistency (r¼0.77–0.93) and test-retest reliability across a
nine-month interval (r¼0.65–0.74) in this sample. In terms of validity, expert
clinical opinion was obtained on the suitability of each item as a measure of
adolescent psychotic experiences to ensure content validity (Ronald et al., 2014).
Furthermore, levels of agreement between scores on SPEQ and the psychosis-like
experiences measure (PLIKS) (a known measure of psychosis-like symptoms)
(Zammit et al., 2011) showed that adolescents who reported “deﬁnitely” having
any psychosis-like symptoms on the PLIKS had signiﬁcantly more PEs on all the
SPEQ subscales (with exception of anhedonia) when compared to those who did
not report any deﬁnite psychosis-like symptoms (all signiﬁcant at po0.001).
Positive and cognitive subscales of PEs showed signiﬁcant positive correlations
with the PLIKS quantitative score (hallucinations r¼0.60, paranoia r¼0.48, cogni-
tive disorganization r¼0.41, grandiosity r¼0.27, all po0.001) (Zammit et al., 2011;
Ronald et al., 2014). Furthermore, for paranoia, cognitive disorganization, grandi-
osity and parent-rated negative symptoms SPEQ subscales, individuals who
reported a family history of psychosis, as measured by having a ﬁrst- or second-
degree relative with schizophrenia or bipolar disorder, scored higher than indivi-
duals without a family history of psychosis (all po0.05) (Zavos et al., 2014). Further
information on the measure can be found in Ronald et al., 2014 (Ronald et al., 2014).
2.3. The twin design
The twin design involves both monozygotic (MZ) and dizygotic (DZ) twin pairs
to determine the extent to which variation in a single phenotype, or covariation
between phenotypes are attributable to genetic and environmental inﬂuences.
Within pair similarities separately for MZ and DZ twin pairs were examined to
establish the role of genetic and environmental inﬂuences based on the notion
that: (1) MZ twin pairs share 100% of their segregating DNA code and DZ twin pairs
share on average 50%; (2) MZ and DZ twin pairs share environmental factors
common to both twins in the same family (‘common environment’); and (3) expo-
sure to environmental factors which are experienced differently or are speciﬁc to
the individual (‘unique environment’) contribute towards differences between MZ
and DZ twin pairs (Plomin et al., 2013).
2.4. Statistical analyses
All analyses were performed using STATA 12 (StataCorp, 2011) and OpenMx
(Boker et al., 2011). OpenMx uses the method of maximum likelihood estimation
and is widely used for analyzing genetically sensitive data. Due to the dichotomous
nature of the cannabis use measure, liability-threshold models were ﬁtted to the
twin data. Liability threshold models assume dichotomous or categorical variables
to have an underlying continuous liability that follows a standard normal
distribution with a mean of 0 and variance of 1. The measured phenotype (i.e.
cannabis use) is assumed to be present amongst those whose liability is above a
certain threshold and absent amongst those whose liability is below the threshold.
Similarities between twin pairs were measured using tetrachoric (dichotomous
measures) or polychoric (categorical measures) correlations, which are then used to
estimate the extent of additive genetic (A), common environment (C) and unique
environmental inﬂuences (E) (Neale and Cardon, 1992).
To facilitate liability threshold models where ordinal data are required, SPEQ
scales were categorized to create ordinal scales where observations were present in
all categories. Based on the sample distribution, standard approaches were
employed to categorize the SPEQ subscales into ordinal variables. Five thresholds
were placed using approximately equal percentiles creating six categories each for
paranoia, hallucinations, cognitive disorganization, grandiosity, and anhedonia.
Four thresholds were placed using approximately equal percentiles creating ﬁve
categories for parent-rated negative symptoms, as the sample distribution for this
scale did not allow for six categories to be created. For example all those who
reported scores in the ﬁrst quartile were categorized as ‘1’, those in the second
quartile were categorized as ‘2’ and so forth. This allowed for liability threshold
models to be adopted for the bivariate association between cannabis use and PEs,
in which the two liabilities are determined by potentially correlated genetic and
environmental components. Thus all twin analyses reported in this manuscript
were conducted using categorized SPEQ subscales.
Structural equation modeling techniques were employed to establish the relative
importance of additive genetic (A), common environment (C) and unique environ-
mental inﬂuences (E) contributing to a phenotype (Plomin et al., 2013). This technique
further extends to bivariate analyses, by exploring the covariation between pheno-
types. It was used to calculate the relative contributions of genetic and environmental
factors to the association between cannabis use and PEs, which are referred to as
bivariate heritability (biva2), bivariate common environment (bivc2) and bivariate
unique environment (bive2). Estimates of covariance between cannabis use and PEs
were also used to calculate genetic correlations (ra), common environment correla-
tions (rc) and unique environment correlations (re), which indexed the extent to which
the same set of genes or environments inﬂuence both phenotypes (Neale and Cardon,
1992). Once parameter estimates were calculated with conﬁdence intervals using the
maximum-likelihood method, the relative ﬁts of different models were compared to a
saturated model (which provides a full description of the data) to establish the best
ﬁtting model to the data (Rijsdijk and Sham, 2002). The best ﬁtting models were
selected based on the lowest Akaike's Information Criterion values (AIC). In instances
where there was a difference of less than 2 in AIC between two models (i.e. ACE
dropped ra and ACE dropped rc), resulting in the relative inﬂuences being difﬁcult to
distinguish (Wagenmakers and Farrell, 2004), the full ACE model was chosen.
Analyses were performed in three steps. First, the extent to which cannabis use
was associated with PEs in adolescence was explored. Speciﬁc PEs that correlated
40.10 with cannabis use were carried forward for twin model-ﬁtting in the next steps.
Second, the degree of twin similarity on the measures separately for MZ and DZ
groups was assessed using tetrachoric and polychoric correlations, respectively and
univariate structural equation models were used to estimate the contributions of
genetic and environmental inﬂuences on cannabis and speciﬁc PEs. Third, a series of
bivariate twin models were performed to test the degree to which genetic and
environmental inﬂuences on cannabis use overlapped with genetic and environmental
inﬂuences on speciﬁc PEs. Sources of covariation were tested ﬁrst using the full ACE
model, followed by the CE, AE, E, ACE dropped ra and ACE dropped rc models.
3. Results
3.1. Phenotypic analyses
In the sample, 9.44% of adolescents reported ‘yes’ to ever using
cannabis. Adolescents who reported ‘yes’ had signiﬁcantly higher
levels of PEs compared to those who reported ‘no’ (Table 1), with
Table 1
Mean levels of psychotic experiences by cannabis use.
Cannabis use T value d.f. p Value Effect size (d)
No Yes
Mean (S.D.) Mean (S.D.)
Psychotic experiences
Paranoia 11.14 (9.95) 15.19 (11.46) 5.82 278.63 o0.01 0.38
Hallucinations 4.30 (5.86) 6.09 (7.13) 3.69 262.42 o0.01 0.27
Cognitive disorganization 3.84 (2.81) 4.82 (2.86) 4.95 277.27 o0.01 0.35
Grandiosity 5.17 (4.31) 5.74 (4.23) 2.23 284.93 0.05 0.13
Anhedonia 33.80 (7.76) 32.28 (8.55) 2.59 270.08 0.01 0.19
Parent-rated negative symptoms 2.69 (3.77) 3.62 (4.46) 3.74 273.68 o0.01 0.23
Note: mean differences presented using continuous scales of psychotic experiences. Signiﬁcant at Bonferroni corrected value of 0.008. d.f.¼Welch's degrees of freedom to
adjust for uneven group sizes.
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the largest effect for paranoia (d¼0.38) and smallest effect for
grandiosity (d¼0.13).
Table 2 presents phenotypic correlations between cannabis use
and PEs. Cannabis use was signiﬁcantly correlated with paranoia,
hallucinations, cognitive disorganization and parent-rated nega-
tive symptoms (r¼0.14–0.22, po0.05); associations were half or
less for anhedonia and grandiosity (r¼0.06–0.07, po0.05).
Behavior genetic analyses were performed on the associations
between cannabis and speciﬁc PEs where the phenotypic correla-
tions were 40.10 to enable covariation to be meaningfully
decomposed into genetic and environmental inﬂuences.
3.2. Genetic and environmental inﬂuences on cannabis use and PEs
For cannabis use, paranoia, hallucinations, cognitive disorgani-
zation and parent-rated negative symptoms, univariate twin
correlations (Table 2) were indicative of genetic inﬂuences (A),
because MZ correlations were consistently larger than DZ correla-
tions. As the DZ correlations were somewhat greater than half of
the MZ correlations for PEs and cannabis use, this suggested some
common environmental (C) inﬂuence. Furthermore, as MZ corre-
lations were less than unity, this implied unique environmental
effects (E) on all scales.
Univariate twin model ﬁtting analyses (Table 3) conﬁrmed
initial observations from the twin correlations (Table 2) by show-
ing that genetic (A¼0.27–0.54) and unique environmental
(E¼0.12–0.50) inﬂuences contributed the most to variance
observed in each of the PEs (shown in ﬁnal column of Table 3).
The model with the most negative AIC ﬁt index was selected as
best ﬁtting. As shown in Table 3 (middle column), the CE model
which does not include genetic inﬂuences ﬁt signiﬁcantly worse
than the ACE model (which includes genetic inﬂuences) indicating
signiﬁcant genetic inﬂuences for all scales. It is not possible to
drop E from univariate models because this term includes mea-
surement error. A small proportion of the variance was explained
by common environment (C¼0.11–0.20), with the exception of
parent-rated negative symptoms (C¼0.42), which showed a larger
effect. Common environmental parameters could be dropped from
the models for paranoia and cognitive disorganization. Genetic
(A¼0.37) and common environmental factors (C¼0.55) explained
the largest proportions of variance in cannabis use, with the
remainder being explained by unique environmental inﬂuences
(E¼0.08) (Table 3). All univariate ACE models did not provide a
signiﬁcantly worse ﬁt compared to the saturated models.
3.2.1. Genetic and environmental inﬂuences on the association
between cannabis use and PEs
Bivariate cross-twin cross-trait (CTCT) correlations (Table 2) pro-
vided an insight into the extent to which the covariance between
cannabis use and PEs was explained by genetic and environmental
inﬂuences. Collectively, MZ CTCT correlations were only marginally
larger than DZ CTCT correlations, which is indicative of little or no
genetic inﬂuence on the phenotypic associations between cannabis
use and PE. DZ CTCT correlations were considerably greater than half
of MZ CTCT correlations thus implying a large common environmental
effect on the covariation. For cannabis use with paranoia, hallucina-
tions and cognitive disorganisation, MZ CTCT correlations were less
than the phenotypic correlations, suggesting unique environmental
inﬂuences on the covariation.
Results from the bivariate correlated factors solution (Table 4)
showed consistently that for the association between cannabis use
and paranoia, as well as with cognitive disorganization and
parent-rated negative symptoms, the ACE correlated factors solu-
tion with dropped ra ﬁtted the data best based on the AIC ﬁt index
(the model with the most negative AIC ﬁt index was selected as
best ﬁtting). This meant that the covariation between cannabis use
and these speciﬁc PEs was not explained by genetic inﬂuences (as
shown by the parameter estimates ‘Bivariate a2’ in Table 5), but
rather by environmental inﬂuences (parameter estimates “Bivari-
ate e2’ and ‘Bivariate e2’ in Table 5). Furthermore, there was no
signiﬁcant overlapping genetic inﬂuences between cannabis use
and these speciﬁc PEs (parameter estimate ‘ra’ in Table 5).
Analyses demonstrated that the relationship between cannabis
use and paranoia and cognitive disorganization was largely
explained by common environmental inﬂuences (bivc2¼0.69–
0.72), with the remaining covariance explained by E, as shown
by the parameter estimates in Table 5, which stem from the best
ﬁtting models selected in Table 4. The common environmental
correlation indicated that a large degree of common environmen-
tal inﬂuences overlapped between the two phenotypes (rc¼0.49–
0.76). Furthermore, a moderate proportion of unique environmen-
tal overlap between cannabis use and paranoia was also found
(re¼0.26–0.31). Similarly the ACE correlated factors solution with
dropped ra ﬁtted the data best, as shown by low AIC value, when
testing the association between cannabis use and parent-rated
negative symptoms (Table 4). Results showed that all of the
covariance was explained by common environmental factors
(bivc2¼1.00), with moderate common environmental (rc¼0.31)
overlap between cannabis use and parent-rated negative symp-
toms (Table 5, Figs 1, 3 and 4 in Supplementary material).
Analyses investigating the relationship between cannabis use
and hallucinations demonstrated that the ACE correlated factors
solution was the best ﬁt. Results showed that the covariance was
explained in part by A, C and E, although conﬁdence intervals
overlapped with zero (Table 5, Fig. 2 in Supplementary material).
Findings showed that the relationship between cannabis use and
Table 2
Phenotypic and twin correlations.
Cannabis use
Correlation (CI) N
Phenotypic correlations
Psychotic experiences
Paranoia 0.22 (0.17, 0.27) 2441
Hallucinations 0.17 (0.11, 0.22) 2445
Cognitive disorganization 0.18 (0.11, 0.24) 2441
Grandiosity 0.07 (0.01, 0.12) 2444
Anhedonia 0.06 (0.12, 0.01) 2443
Parent-rated negative symptoms 0.14 (0.08, 0.20) 2430
Twin correlations
MZ DZ
Correlation (CI) Correlation (CI)
Univariate twin correlations
Psychotic experiences
Paranoia 0.54 (0.50, 0.58) 0.30 (0.25, 0.35)
Hallucinations 0.48 (0.43, 0.52) 0.33 (0.28, 0.38)
Cognitive disorganization 0.50 (0.46, 0.54) 0.30 (0.25, 0.35)
Parent-rated negative symptoms 0.88 (0.87, 0.90) 0.63 (0.60, 0.67)
Cannabis 0.92 (0.88, 0.95) 0.74 (0.65, 0.82)
Cross-trait cross-twin correlations
Psychotic experiences and cannabis
Paranoia 0.17 (0.10, 0.23) 0.15 (0.08, 0.22)
Hallucinations 0.15 (0.08, 0.21) 0.10 (0.03, 0.17)
Cognitive disorganization 0.13 (0.06, 0.19) 0.12 (0.04, 0.28)
Parent-rated negative symptoms 0.14 (0.07, 0.20) 0.18 (0.11, 0.24)
Note: phenotypic correlations were performed using one random member of each
twin pair. CI¼conﬁdence intervals.
All genetic analyses (including phenotypic and twin correlations) were performed
using ordinal scales of PEs.
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hallucinations was familial, however it was not possible to
differentiate between genetic and shared environmental effects.
4. Discussion
This study investigated the extent to which genetic and
environmental factors can explain the relationship between can-
nabis use and speciﬁc psychotic experiences (PEs) in adolescence.
In keeping with previous studies (Fergusson et al., 2003; Stefanis
et al., 2004; Henquet et al., 2005a, 2005b; Hides et al., 2009; Van
Gastel et al., 2012; Grifﬁth-Lendering et al., 2013) cannabis use was
associated with higher levels of positive, cognitive, and negative
PEs. We observed similar modest correlations as previous studies
(Grifﬁth-Lendering et al., 2013), reinforcing the idea that cannabis
use explains a small amount of variance in speciﬁc PEs. Between
2% and 5% of variance was explained for paranoia, hallucinations,
cognitive disorganization and parent-rated negative symptoms;
under 1% for anhedonia and grandiosity. In addition, to account for
possible confounders driving the observed associations between
cannabis use and PEs, adjusted phenotypic analyses demonstrated
that the bivariate associations between cannabis use and PEs were
not signiﬁcantly confounded by the effects of socioeconomic status
and family history of psychosis (See Supplementary Table S1).
As adolescence is a ‘window of vulnerability’ for neurodevelop-
ment due to physical, social and psychological changes (Casey
et al., 2008), it is possible that cannabis use is contributing to PEs
through its effect on brain chemistry (Iversen, 2003; Bowers and
Kantrowitz, 2007). However, it is important to keep in sight that
PEs may also inﬂuence cannabis use, and that the path underlying
the association between cannabis use and PEs may differ depend-
ing on temporal priority. For example when PEs are ﬁrst emerging
cannabis may be associated with PEs through their inﬂuence on
brain chemistry. Once PEs are more prevalent or prominent,
cannabis may begin to be used as a tool for coping with the
psychological distress through means of ‘self-medication’. The
present study speaks to the association cross-sectionally at age-
16 years. Future work should explore the etiological underpin-
nings of the relationship between cannabis and PEs longitudinally.
Cannabis use and PEs were in part heritable, as suggested by
previous studies (Polanczyk et al., 2010; Ericson et al., 2011;
Verweij et al., 2011; Hur et al., 2012) with the remaining variance
for PEs largely attributable to unique environmental factors, and
also common environmental factors for parent-rated negative
symptoms and cannabis use. Our ﬁndings demonstrate that the
relationship between cannabis use in adolescence and paranoia,
cognitive disorganization and parent-rated negative symptoms is
explained by common and unique environmental inﬂuences.
These ﬁndings were in contrast to the hypothesis that PEs and
Table 3
Fit statistics and parameter estimates for best ﬁtting univariate models: psychotic experiences and cannabis use.
Model Model ﬁt
Compared to saturated model Compared to ACE model Univariate parameter estimates
2LL d.f. LRT Δd.
f.
AIC p LRT Δd.
f.
AIC p A (CI) C (CI) E (CI)
Paranoia Sat 22,662.50 6515 – – – – – – – – –
ACE 22,678.88 6530 16.38 15 13.62 0.36 – – – 0.46
(0.34,0.57)
0.08
(0.01,0.18)
0.46
(0.43,0.50)
CE 22,734.61 6531 72.11 16 40.11 o0.01 55.73 1 53.73 o0.01 – – –
AEa 22,680.95 6531 18.45 16 13.55 0.30 2.07 1 0.07 0.15 0.54
(0.51,0.58)
– 0.46
(0.42,0.49)
Hallucinations Sat 22,312.35 6525 – – – – – – –
ACEa 22,326.96 6540 14.60 15 15.40 0.48 – – – 0.27
(0.14,0.39)
0.20
(0.10,0.31)
0.53
(0.49,0.57)
CE 22,344.02 6541 31.67 16 0.33 0.01 17.06 1 15.06 o0.01 – – –
AE 22,340.18 6541 27.83 16 4.17 0.03 13.22 1 11.22 o0.01 – – –
Cognitive disorganization Sat 22,190.41 6516 – – – – – – – – –
ACEa 22,210.01 6531 19.61 15 10.39 0.19 – – – 0.39
(0.27,0.52)
0.11
(0.01,0.21)
0.50
(0.46,0.54)
CE 22,248.08 6532 57.67 16 25.67 o0.01 38.07 1 36.07 o0.01 – – –
AE 22,214.01 6532 23.61 16 8.39 0.10 4.00 1 2.00 0.05 – – –
Parent-rated negative
symptoms
Sat 17,703.14 6528 – – – – – – – – –
ACEa 17,710.15 6540 7.00 12 15.00 0.86 – – – 0.46
(0.39,0.54)
0.42
(0.34,0.48)
0.12
(0.11,0.13)
CE 17,934.96 6541 231.81 13 205.81 o0.01 224.81 1 222.81 o0.01 – – –
AE 17,801.98 6541 98.84 13 72.84 o0.01 91.83 1 89.83 o0.01 – – –
Cannabis Sat 2516.56 4891 – – – – – – – – – – –
ACEa 2521.56 4894 5.01 3 0.99 0.17 – – – 0.37
(0.20,0.57)
0.55
(0.36,0.70)
0.08
(0.05,0.12)
CE 2541.385 4895 24.83 4 16.83 o0.01 19.82 1 17.82 o0.01 – – –
AE 2547.885 4895 31.32 4 23.32 o0.01 26.32 1 24.32 o0.01 – – –
Note: additive genetic inﬂuences (A), common environmental inﬂuences (C), and unique environmental inﬂuences (E) shown in the right hand column of the table for each
scale. Sat¼saturated model; ACE¼ full model testing genetic, common and unique environmental inﬂuences; AE¼model testing genetic and unique environment inﬂuences;
CE¼model testing common and unique environmental inﬂuences; 2LL¼negative 2 log likelihood; d.f.¼degrees of freedom; LRT¼ likelihood ratio chi-square test
comparing the 2LL ﬁt of each model to the 2LL ﬁt of the saturated model; Δd.f.¼difference in degrees of freedom comparing each model to the saturated model;
AIC¼Akaike's Information Criterion (lower values reﬂect a better ﬁt); p¼p-value. A¼additive genetic inﬂuences, C¼common environmental inﬂuences, E¼Unique
environmental inﬂuences.
a Best ﬁtting model. 95% Conﬁdence intervals in parentheses.
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cannabis use co-occur due to a similar underlying genetic liability.
The absence of a shared genetic propensity underlying the
association between cannabis use and PEs may be explained by
the age of our adolescent sample, as common environmental
factors have been identiﬁed to have a more prominent role in
the initiation and early patterns of cannabis use in comparison to
Table 4
Fit statistics and parameter estimates for best ﬁtting bivariate models: psychotic experiences and cannabis use.
Model Model ﬁt
Compared to saturated model Compared to ACE model
2LL d.f. LRT Δd.f. AIC p LRT Δd.f. AIC p
Paranoia Saturated 25,137.56 11,416 – – – – – – – –
ACE 25,140.19 11,421 2.64 5 7.36 0.76 – – – –
CE 25,217.50 11,424 79.94 8 63.94 o0.01 77.31 3 71.31 o0.01
AE 25,169.43 11,424 31.87 8 15.87 o0.01 29.24 3 23.24 o0.01
E 26,200.45 11,427 1062.89 11 1040.00 o0.01 1060.25 6 1048.25 o0.01
ACE dropped raa 25,140.39 11,422 2.83 6 9.17 0.83 0.20 1 1.80 0.65
ACE dropped rc 25,144.10 11,422 6.54 6 5.46 o0.01 3.91 1 1.91 o0.01
ACE dropped ra and rc 25,171.31 11,423 33.75 7 19.75 o0.01 31.11 2 27.11 o0.01
Hallucinations Saturated 24,810.19 11,426 – – – – – – – –
ACEa 24,814.27 11,431 4.08 5 5.92 0.54 – – – –
CE 24,851.21 11,434 41.02 8 25.02 o0.01 36.94 3 30.94 o0.01
AE 24,854.17 11,434 43.98 8 27.98 o0.01 39.90 3 33.90 o0.01
E 25,761.78 11,437 951.59 11 929.59 o0.01 947.51 6 935.51 o0.01
ACE dropped ra 24,815.78 11,432 5.59 6 6.41 0.47 1.51 1 0.49 0.22
ACE dropped rc 24,815.00 11,432 4.81 6 7.19 0.57 0.73 1 1.27 0.39
ACE dropped ra and rc 24,835.83 11,433 25.63 7 11.63 o0.01 21.55 2 17.55 o0.01
Cognitive disorganization Saturated 24,680.60 11,417 – – – – – – – –
ACE 24,692.72 11,422 12.12 5 2.12 0.03 – – – –
CE 24,751.53 11,425 70.93 8 54.93 o0.01 58.80 3 52.80 o0.01
AE 24,723.91 11,425 43.31 8 27.31 o0.01 31.19 3 25.19 o0.01
E 25,676.70 11,428 996.11 11 974.11 o0.01 983.98 6 971.98 o0.01
ACE dropped raa 24,692.80 11,423 12.21 6 0.21 0.06 0.08 1 1.92 0.77
ACE dropped rc 24,695.19 11,423 14.60 6 2.60 o0.01 2.47 1 0.47 0.12
ACE dropped ra and rc 24,711.06 11,424 30.47 7 16.47 o0.01 18.34 2 14.34 o0.01
Parent-rated negative symptoms Saturated 20,205.32 11,426 – – – – – – – –
ACE 20,208.79 11,431 3.46 5 6.54 0.63 – – – –
AE 20,331.66 11,434 126.33 8 110.33 o0.01 122.87 3 116.87 o0.01
CE 20,456.55 11,434 251.23 8 235.23 o0.01 247.77 3 241.77 o0.01
E 22,987.32 11,437 2781.99 11 2759.99 o0.01 2778.53 6 2766.53 o0.01
ACE dropped raa 20,209.82 11,432 4.49 6 7.51 0.61 1.03 1 0.97 0.31
ACE dropped rc 20,220.86 11,432 15.54 6 3.54 0.02 12.08 1 10.08 o0.01
ACE dropped ra and rc 20,231.84 11,433 26.52 7 12.52 o0.01 23.06 2 19.06 o0.01
Note: Sat¼saturated model, ACE¼ full model testing genetic, common and unique environmental inﬂuences; AE¼model testing genetic and unique environment inﬂuences;
CE¼model testing common and unique environmental inﬂuences; ACE dropped ra¼ full model testing genetic, common and unique environmental inﬂuences with genetic
correlation ﬁxed to 0; ACE dropped rc¼ full model testing genetic, common and unique environmental inﬂuences with common environmental correlation ﬁxed to 0; ACE
dropped rea and rc¼full model testing genetic, common and unique environmental inﬂuences with genetic and common environmental correlations ﬁxed to 0;
2LL¼negative 2 log likelihood; d.f.¼degrees of freedom; LRT¼ likelihood ratio chi-square test comparing the 2LL ﬁt of each model to the 2LL ﬁt of the saturated
model; Δd.f.¼difference in degrees of freedom comparing each model to the saturated model; AIC¼Akaike's Information Criterion (lower values reﬂect a better ﬁt); p¼p-
value.
a Best ﬁtting model. 95% Conﬁdence intervals in parentheses.
Table 5
Parameter estimates for best ﬁtting bivariate models: psychotic experiences and cannabis use.
Cannabis use
Best ﬁtting
model
Bivariate a2 Bivariate c2 Bivariate e2 ra rc re
Paranoia ACE dropped ra – 0.72 (0.55, 0.88) 0.28 (0.12, 0.45) – 0.76 (0.40, 1.00) 0.31 (0.13, 0.48)
Hallucinations ACE 0.54 (0.35,
1.47)
0.33 (0.48, 1.10) 0.13 (0.13, 0.40) 0.29 (0.19,
0.78)
0.17 (0.24, 0.57) 0.11 (0.10, 0.31)
Cognitive disorganization ACE dropped ra – 0.69 (0.47, 0.88) 0.31 (0.12, 0.53) – 0.49 (0.24, 1.00) 0.26 (0.09, 0.42)
Parent-rated negative
symptoms
ACE dropped ra – 1.00 (0.85, 1.19) 0.00 (0.19, 0.15) – 0.31 (0.18, 0.46) 0.00 (0.23, 0.21)
Note: ACE¼ full model testing genetic, common and unique environmental inﬂuences; ACE dropped ra¼ full model testing genetic, common and unique environmental
inﬂuences with genetic correlation ﬁxed to 0; bivariate genetic (bivariate a2), common environment (bivariate c2) and unique environment (bivariate e2) estimated indicate
the proportion of phenotypic correlations explained by genetics, common and unique environment, respectively. Bivariate genetic (ra), common environment (rc) and unique
environment (re) correlations indicate the genetic and environmental overlap between psychotic symptoms and cannabis use. A correlation of ‘0’ is indicative of no overlap
and a correlation of ‘1’ is indicative of complete overlap in either genetic or environmental inﬂuences. 95% conﬁdence intervals in parentheses.
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in adults where it is more heritable (Kendler et al., 2008). These
ﬁndings reinforce the argument that cannabis use is an ‘environ-
mental’ risk indicator for PEs in adolescence and suggests a role of
other ‘environmental’ correlates involved in shaping the path
between cannabis use and PEs in adolescents.
The ﬁnding that a signiﬁcant proportion of overlapping envir-
onmental inﬂuences provides support for research aiming to
identify environmental factors which are associated with both
cannabis use and PEs, such as peer victimization (Tharp-Taylor
et al., 2009; Arseneault et al., 2011) and socioeconomic disadvan-
tage (Daniel et al., 2009; Morgan et al., 2009). Exposure to
socioeconomic disadvantage may induce stress that triggers the
development of PEs and cannabis use. Furthermore there is
evidence to suggest that cannabis use can increase the risk of
trauma (i.e. maltreatment) based vulnerabilities for psychosis
(Shevlin et al., 2009). Although psychotic experiences are not the
same as clinical psychosis, it is feasible to suggest that trauma may
be an ‘environmental’ risk factor which contributes towards the
association between cannabis use and psychotic experiences, and
warrants further investigation. Further investigation into other
common environmental correlates of cannabis use and PEs as
potential underlying mechanisms may aid a better understanding
of the association between cannabis use and PEs. The next step is
to investigate the mechanisms by which these overlapping envir-
onmental factors operate, which could be environmentally ind-
uced but biologically based, such as environmentally induced
changes to the epigenome and transcriptome.
Our study has some limitations. We used a categorical measure of
cannabis use, which captured cannabis use and did not account for
other contributory factors such as potency or regularity of use. It is
relevant to consider whether a measure of cannabis use will be
inﬂuenced in part by availability of cannabis and temperament of the
individual more so than a measure of frequency of cannabis use. A
more detailed measure tapping into these contributory factors would
have provided more information about exposure. However, our
prevalence estimate of 9.44% is in line with the 9.50% prevalence
rate of lifetime cannabis use reported by other population-based
studies where detailed measures of cannabis use was collected
(Hides et al., 2009). In addition, the potential limitation that
hallucinations, paranoia, and cognitive disorganization subscales
did not specify a time-frame for endorsement should be noted.
Lastly, it is possible that the associations observed between cannabis
use and PEs may have been inﬂuences by tobacco use. Our study did
not account for the potential confounding effect of tobacco as tobacco
use is intertwined with most cannabis use.
This study also has a number of strengths. Using a genetically
informative study twin design, this study decomposed the rela-
tionships between cannabis use and PEs into genetic and environ-
mental inﬂuences. Furthermore, in contrast to other studies that
have focused on a speciﬁc type of psychotic experience, such as
hallucinations (Shevlin et al., 2007), this study included a wide
array of speciﬁc PEs, which were measured as dimensions and
included positive, cognitive and negative PEs.
A challenge facing researchers and practitioners alike is to
identify individuals at risk of severe PEs and later psychosis prior
to their onset. In particular it is imperative to understand the
causes of PEs amongst adolescents, as identifying individuals at
risk of psychotic disorders at an early age could be important for
preventing adult onset of psychotic disorders such as schizophre-
nia. Findings from this study suggest that drawing attention to
‘environmental’ factors, which are common to both cannabis use
and PEs, may be potential targets for future policy programs. It is
important to note that this study investigated the association
between cannabis use and PEs and not clinical psychosis. Findings
should therefore be interpreted with the view of PEs as trait based
phenotypes, and not clinical psychosis.
Behavior genetic designs such as the discordant monozygotic
twin design or adoption designs would be ideal because they are
the most powerful means of studying environmental inﬂuences
independently of genetic effects (Plomin et al., 2013). Further twin
studies on the association between PEs and cannabis use are
needed in older age groups to test the causes underlying their
relationship in late adolescence and in adulthood.
In conclusion, this study found cannabis use in adolescence to
be associated with elevated PEs, speciﬁcally paranoia, hallucina-
tions, cognitive disorganization and negative symptoms. Cannabis
use co-occurs with PEs in adolescence due to environmental risk
factors that are common to both. These data argue against the
hypothesis that psychotic experience and cannabis use co-occur
due to a similar underlying genetic liability in adolescence and
highlight adolescence as a developmental period where environ-
mental processes are signiﬁcant.
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